Sumitomo Dainippon Pharma Annual Report 2017
53/102

ISO26000 Core Subjects Applicable item ofthe “Declaration of Conduct”Principal ActivitiesPageCSR Activities http://www.ds-pharma.com/csr/ISO26000 Core Subjects and Principal ActivitiesHuman Rights•Respect for Human Rights•Eradicating All Forms of Discrimination•Clinical Studies Put the Human Rights of Subjects First•Respect for Human Rights in Supply Chain Labor Conditions•Initiatives to Prevent Harassment•Building Good Relationship with the Labor UnionP.22P.30Declaration of ConductDeclaration of ConductDeclaration of ConductDeclaration of Conduct1245Labor Practices•Creating a Workplace Environment That Allows Employees to Focus Condently on Their Work•Implementing Health and Safety Risk Assessments•Supporting the Betterment and Growth of Employee Health and Mental Wellbeing•Promoting Dialogue between Management and Employees•Promoting “Work Style Reforms” (improve usage rate of paid leave, prevent overwork, etc.)•Promoting Employment of Persons with Disabilities•Promoting Diversication•Operating of Consultation Desks and HotlinesP.6P.17-18P.53-54Declaration of ConductDeclaration of ConductDeclaration of ConductDeclaration of Conduct1345Environment•Basic Environmental Policies•Environmental Accounting•Perspective on Environmental Impact•Mid-term Environmental Plan•Activities to Conserve Energy and Contribute to Addressing Global Warming•Effective Use of Resources•Initiatives on Biodiversity•Initiatives on Water ResourcesP.30P.58-60Declaration of ConductDeclaration of ConductDeclaration of ConductDeclaration of Conduct1367Fair Operating Practices•Appropriate Information Disclosure and Management•Protecting and Managing Personal Information•Preventing the Falsication and Leakage of Information•Corporate Activities Attaching Importance to Transparency•Establish Proper Relationships with Medical Institutions and Patient Groups•Fair Promotion Activities•Implementing “Ethics in Procurement” as part of CSR Procurement•Respect for Intellectual Property Rights•Reinforcement of Information SecurityP.29-30P.32P.36P.38P.39P.46-48Declaration of ConductDeclaration of ConductDeclaration of Conduct123Consumer Issues•Initiatives to Improve Access to Healthcare•Contributing to the United Nations’ Sustainable Development Goals (SDGs)•Initiatives to Provide High-quality Pharmaceuticals•Encouragement of Proper Use of Pharmaceuticals•Recognizing and Understanding the Needs of Customers•Running a Medical Information Website, a Health Information Website, and a Pharmaceuticals Information Center•Ethical Considerations in Human Tissue Research, Animal Experimentation, and so onP.5P.18P.22P.30P.31-32P.51P.56Declaration of ConductDeclaration of ConductDeclaration of Conduct123Community Involvement and Development•Our Policy on Social Contribution Activities•Stakeholder Engagement•Stakeholder Dialogue•Initiatives for Global Health•Support through Employee Participation•Support through Donation•Social Support•Activities of Global Group CompaniesP.5P.18P.32P.38P.45P.53P.57-58Declaration of ConductDeclaration of ConductDeclaration of ConductDeclaration of ConductDeclaration of Conduct12467Organizational Governance•Implementation of Japan’s Corporate Governance Code•Optimizing the Management Structure, Audit System, and Internal Control Systems•Risk Management•Compliance Implementation•Appropriate Information Disclosure and ManagementP.17P.41-48Declaration of ConductDeclaration of ConductDeclaration of ConductDeclaration of ConductDeclaration of ConductDeclaration of ConductDeclaration of Conduct123456752Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#53

このブックを見る